The primary objective of this study is to evaluate the efficacy of psilocybin (25 mg) administered under supportive conditions to adult participants with severe TRD, in improving depressive symptoms.
Compound Psilocybin
Country United States of America
Visit trial
Status
Recruiting
Results Published
Start date
01 March 2021
End date
01 January 2022
Chance of happening
100%
Phase
Phase II
Design
Open
Type
Interventional
Generation
First
Participants
15
Sex
All
Age
18- 65
Therapy
Yes
Trial Details
The primary objective of this study is to evaluate the efficacy of psilocybin (25 mg) administered under supportive conditions to adult participants with severe TRD, in improving depressive symptoms.NCT Number NCT04433858
Sponsors & Collaborators
COMPASS PathwaysCOMPASS Pathways is a publicly listed company (NASDAQ) that is developing psilocybin for treatment-resistant depression (TRD) for which it has completed a successful Phase IIb trial. COMPASS is one of the largest psychedelic companies and has received substantial investment from atai.
Sheppard Pratt Health System
This company doesn't have a full profile yet, it is linked to a clinical trial.
Measures Used
Montgomery-Asberg Depression Rating ScaleA ten-item diagnostic questionnaire used to measure the severity of depressive symptoms in patients with mood disorders.